SAN
DIEGO, Sept. 25, 2023 /PRNewswire/
-- Avidity Biosciences, Inc. (Nasdaq: RNA), a
biopharmaceutical company committed to delivering a new class of
RNA therapeutics called Antibody Oligonucleotide Conjugates
(AOCs™), today announced that Avidity management will be
participating at the following upcoming conferences:
- Chardan 7th Annual Genetic Medicines Conference
on October 3 at
6:00 a.m. PT/9:00 a.m. ET
- BMO Biopharma Spotlight Series: (R)Evolution of RNA
Therapies on October 10
at 8:00 a.m. PT/11:00 a.m. ET
A live webcast for the Chardan 7th Annual Genetic
Medicines Conference, and an archived replay of both webcasts, will
be available on Avidity's website at
https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is
to profoundly improve people's lives by delivering a new class of
RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™).
Avidity is revolutionizing the field of RNA with its proprietary
AOCs, which are designed to combine the specificity of monoclonal
antibodies with the precision of oligonucleotide therapies to
address targets and diseases previously unreachable with existing
RNA therapies. Utilizing its proprietary AOC platform, Avidity
demonstrated the first-ever successful targeted delivery of RNA
into muscle and is leading the field with clinical development
programs for three rare muscle diseases: myotonic dystrophy type 1
(DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral
muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs
with its advancing and expanding pipeline including programs in
cardiology and immunology through internal discovery efforts and
key partnerships. Avidity is headquartered in San Diego,
CA. For more information about our AOC platform, clinical
development pipeline and people, please
visit www.aviditybiosciences.com and engage with us
on LinkedIn and X (formerly Twitter).
Investor Contact:
Geoffrey
Grande, CFA
(619) 837-5014
investors@aviditybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-301936869.html
SOURCE Avidity Biosciences, Inc.